A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268Phase 2/3Recruiting
- Lead sponsor
- Biohaven Therapeutics Ltd. (Industry)
- Enrollment
- 550 (estimated)
- Start date
- 28 May 2025
- Primary completion
- Aug 2027 (estimated)
- Study completion
- 1 Sep 2028
- Last update posted
- 22 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 3
Interventions
- BHV-8000 10mg Drug
- BHV-8000 20 mg Drug
- Placebo Drug
Conditions and primary outcome
- Parkinson Disease
Primary outcome
Time to first qualifying worsening event on Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II (Up to 48 Weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06976268.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06976268 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.